TD Cowen analyst Yaron Werber reiterated a Buy rating on IO Biotech (IOBT – Research Report) yesterday. The company’s shares closed yesterday at $1.61.
According to TipRanks, Werber is ranked #122 out of 8350 analysts.
Currently, the analyst consensus on IO Biotech is a Strong Buy with an average price target of $11.33, which is a 603.73% upside from current levels. In a report released yesterday, H.C. Wainwright also maintained a Buy rating on the stock with a $11.00 price target.
See the top stocks recommended by analysts >>
IOBT market cap is currently $59.07M and has a P/E ratio of -0.89.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.
Read More on IOBT:
